Responsibility & ESG

ESG Highlights 2023

ENVIRONMENT

  • 14% of electricity consumption covered by own photovoltaic system in 2023
  • Reduction of air travel by 26% compared to 2022

SOCIAL

  • Gender Diversity Index Austria 2023: Marinomed again among top ten
  • Share of women on the Supervisory Board at 60%

GOVERNANCE

  • Implemented digital whistleblowing system
  • New rules of procedure for the Management Board and Supervisory Board with a greater focus on sustainability

Sustainability Report 2023

Sustainability at Marinomed

We are convinced that we can only be successful in the long term through sustainable developments. In all our decisions, we consider aspects that are not only beneficial for the Company or our stakeholders, but are also guided by the impact our actions have on our employees, our environment and our reputation as a Company.

Our vision and primary goal is to protect and improve the health and well-being of people. With our technologies and innovations, we want to address diseases that have so far been insufficiently treated, improve existing therapies and give as many people as possible access to high-quality treatments. With this objective, we pursue a sustainable strategy from the ground up. This continues in the other aspects of our corporate governance, as this report will show. Decisions are continuously reviewed for sustainability aspects and regularly addressed by the Management Board and Supervisory Board. We also intend to incorporate sustainability criteria into important corporate guidelines, such as the remuneration policy and the rules of procedure for the Management Board and Supervisory Board. For example, the Supervisory Board has already linked parts of the variable remuneration of the Management Board for 2022 to the sustainable development goals of the Company.

The Company has extensive expertise in virology and immunology and an active pipeline based on its Carragelose and Marinosolv technology platforms. The success of its product development is reflected in a marketed OTC portfolio as well as other products already in the authorization process. We are working hard on translating our expertise into innovation and thus make our contribution to a future worth living.

Overview of the most important SDG goals that Marinomed pursues with its sustainability strategy. The length of the bars corresponds to the importance of the topics for Marinomed.

Corporate Governance

Marinomed is committed to the rules of the Austrian Corporate Governance Code in the version of January 2018 and complies with all rules required by law (L-Rules) and to a large extent with the rules required by the Code (C-Rules). C-Rules that have not yet been fully complied with are consistently reviewed and their treatment explained in the Corporate Governance Report. 

Whistleblower system

Misconduct at Marinomed - especially systematic misconduct - has not been tolerated in the past and will not be tolerated in the future. Nevertheless, it cannot be ruled out that we observe behaviour in our daily work that we may judge to be misconduct or wrongdoing. We have set up a system that provides employees of Marinomed as well as external contractors or other stakeholders with the opportunity to report incidents that they judge to be misconduct or wrongdoing. We would like to encourage you to make an active and valuable contribution so that we can jointly identify and remedy any misconduct and wrongdoing and thus meet the high standards we set ourselves.

Directors’ Dealings:

20.04.2023 - Brigitte Ederer / Member of an administrative or supervisory board
(146 KB)
15.09.2022 - Brigitte Ederer / Member of an administrative or supervisory board
(134 KB)
15.12.2021 - Brigitte Ederer / Member of an administrative or supervisory board
(76 KB)
02.12.2021 - Pascal Schmidt / CFO
(187 KB)
02.12.2021 - Eva Prieschl-Grassauer / CSO
(187 KB)
02.12.2021 - Andreas Grassauer / CEO
(187 KB)
16.12.2020 - Andreas Grassauer / CEO
(733 KB)
16.12.2020 - Eva Prieschl-Grassauer / CSO
(732 KB)
16.12.2020 - Pascal Schmidt / CFO
(732 KB)
27.01.2020 - Brigitte Ederer / Member of an administrative or supervisory board
(301 KB)
18.10.2019 - Karl Lankmayr / Member of an administrative or supervisory board
(304 KB)
18.10.2019 - Gernot Hofer / Member of an administrative or supervisory board
(303 KB)
20.02.2019 - Simon Nebel / Chairman of the supervisory board
(304 KB)
20.02.2019 - Ute Lassnig / Member of an administrative or supervisory board
(305 KB)
01.02.2019 - Gernot Hofer / Member of an administrative or supervisory board
(43 KB)
01.02.2019 - Karl Lankmayr / Member of an administrative or supervisory board
(43 KB)
31.01.2019 - Simon Nebel / Chairman of the supervisory board
(42 KB)
30.01.2019 - Ute Lassnig / Member of an administrative or supervisory board
(22 KB)
Lucia Ziegler, MSc
Head of Investor & Public Relations
Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg, Austria
+43 2262 90300
office@marinomed.com